Nanobiotix is a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform cancer treatment.
NBTXR3 – Nanobiotix’s novel, first-in-class lead product candidate aims to expand the benefits of radiotherapy for millions of cancer patients. NBTXR3 is being evaluated both as a single agent activated by radiotherapy alone, and as a combination product with other anti-cancer therapies including chemotherapy and immune checkpoint inhibitors.
The company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany.
* Bulletin Officiel des Finances Publiques – Impôts, BOI-RPPM-RCM-40-55, and decree no. 2014-283 dated March 4, 2014 (i.e. less than 5,000 employees, annual revenue of less than EUR1,500M or total balance sheet of less than EUR2,000M). The PEA-PME is a French tax-incentivized financial framework that aims at diversifying companies’ funding sources, specifically small and medium-sized companies. Shares issued by Nanobiotix and listed on Euronext Paris consequently remain eligible for inclusion into PEA-PME accounts, which benefit from the same tax regime as standard PEA accounts, subject to the personal situation of each relevant shareholder. Please note that American Depositary Shares are not eligible to this regime.
SHAREHOLDING STRUCTURE (DEC 2021)
Management & Employees5%
|Issued Shares: 34 825 872|
NANOBIOTIX ANALYST COVERAGE
|Degroof Petercam (BE)||David Seynnaeve|
|Evercore ISI (US)||Jonathan Miller|
|Gilbert Dupont (FR)||Guillaume Cuvillier|
|H.C. Wainwright & Co. (US)||Ramakanth Swayampakula|
|Jefferies (UK)||Lucy Codrington|
|Kempen (NL)||Ingrid Gafanhao|
|UBS (US)||Colin Bristow|
|Shareholders||% of Share Capital||% of Voting Rights|
|Caisse des Dépôts||5.52%||5.34%|
*Allocation to reference shareholders (above 5%) as of December 2021
Recent Press Releases
ALL NANOBIOTIX PRESS RELEASES